Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace Directory

Beckman’s Early Sepsis Indicator gets CE mark

July 2018—Beckman Coulter announced its Early Sepsis Indicator received the CE mark. The Early Sepsis Indicator is a hematology-based solution designed to alert emergency department clinicians to the possibility of sepsis or risk of developing sepsis and is to be offered as part of a routine CBC with differential test.

Quantimetrix launches Dipper POCT

July 2018—Quantimetrix announced the launch of its Dipper POCT Single-Use Liquid Urinalysis Dipstick Control for use in a variety of testing environments, including central labs, reference labs, nursing stations, and doctors’ offices.

Meridian launches TruBlock Ready

July 2018—Meridian Life Science launched TruBlock Ready, a broad-acting HAMA blocker that is ready to use within a single dilution step.

Parainfluenza virus antigens

July 2018—Binding Site’s Immunologicals Group has added three parainfluenza virus antigens for in vitro diagnostic manufacturing and research applications. The Parainfluenza Virus Type 1, Type 2, and Type 3 antigens have been designed for use in solid phase enzyme immunoassay test procedures, especially ELISAs.

Fujirebio, Janssen team up

July 2018—Fujirebio has entered into an agreement with Janssen Pharmaceuticals to develop and commercialize an amyloid β 42/40 ratio assay. The assay will run on the Lumipulse series

PLUGS, Metis join forces

July 2018—PLUGS (Patient-centered Laboratory Utilization Guidance Services) and Metis Genetics announced a partnership to provide case review services via Gene­Test­Advisor, a case management solution for genetic testing to support health care systems and insurance payers in effectively administering their genetic testing caseload.

POC hemoglobin analyzer

June 2018—EKF Diagnostics announced FDA 510(k) clearance and CLIA waiver for its Dia­Spect handheld hemoglobin analyzer.